Abstract 2278P
Background
The heterogeneity of the tumor microenvironment is a major barrier for effective cancer therapies. Similar to the immune tumor microenvironment the stromal environment, composed of cancer-associated fibroblasts (CAFs), pericytes, adipocytes and endothelial cells, is also heterogeneous. Multiple studies showed that CAFs contain heterogenous cell populations with opposing pro and anti-tumoral function. The heterogeneity of endothelial cells (ECs) is less well described largely due to the relative low frequencies in tumor tissues compare to CAFs. We set out to study the heterogeneity of the tumor microenvironment using truly single-cell spatial transcriptomic by the 10x Genomics Xenium platform.
Methods
We analyzed 20 human breast tumors by Xenium single-cell analyzes using fluorescent in situ sequencing (FISSEQ). We used the available breast panel that contains 280 genes, with 8 probes for each gene. The analysis of the data was preformed using the Seurat pipeline in R (version 4.9.9.9039).
Results
We could readily identify blood vessel structures that surrounded PECAM1/VWF positive cells. After multiple clustering we identified five types of endothelial cells with divergent gene expression profiles. We defined the following clusters of ECs: 1) Proliferating ECs, 2) CXCL12+ ECs, 3) POSTNHi/VWFHi ECs, 4) TPD52Hi ECs and POSTNLow/VWFHi ECs. The endothelial cells also showed spatial variations in distribution. Data on EC subtypes will correlation and other cell types and cell neighborhoods will be presented.
Conclusions
ECs in breast cancer tumors are highly heterogeneous and can be further classified into functionally divergent subtypes, potentially contributing to the heterogenous responses observed to treatments.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
CHUV.
Funding
CHUV.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2315P - Clinical and blood immune-inflammatory profiling to decode different patterns of acquired resistance in immunotherapy treated NSCLC patients
Presenter: Giulia Mazzaschi
Session: Poster session 08
2316P - Integrating comprehensive cancer genome profiling into clinical practice in an Italian referral center: Results of the first year of the fpg500 programme
Presenter: Camilla Nero
Session: Poster session 08
2317P - Mutational landscape and therapeutic implications in squamous cell carcinomas
Presenter: Laila Belcaid
Session: Poster session 08
2318P - Value of broad molecular profiling for cancer diagnosis
Presenter: Lars Volker Anton Werstein
Session: Poster session 08
2319P - CADSP: A web tool for comprehensive drug sensitivity analysis in pan-cancer
Presenter: Kexin Li
Session: Poster session 08
2320P - Detection of gene fusion-induced neoepitopes in dedifferentiated liposarcoma
Presenter: Peter Horak
Session: Poster session 08
2321TiP - TEMPLE: Thiopurine enhanced mutations for PD-1/ligand-1 efficacy: A phase Ib/II clinical trial
Presenter: Christine Federspiel Secher
Session: Poster session 08
2322TiP - SOUND: A phase II trial evaluating the efficacy of molecular profiling of circulating ± tumor tissue DNA for salvage-therapy matching in patients with advanced and refractory carcinoma
Presenter: Jakob Riedl
Session: Poster session 08